Early Signs For Takeda’s TAK-875 Suggest The GPR40 Agonist Could Take On Other Oral Antidiabetics
This article was originally published in The Pink Sheet Daily
Takeda’s novel GPR40 agonist TAK-875 has proven in Phase II to have blood sugar lowering on par with widely prescribed sulfonylureas, without causing hypoglycemia, and now moves into Phase III.
You may also be interested in...
Latest “complete response” letter for Takeda’s DPP-4 inhibitor is “not specific” to cardiovascular outcomes. But the delay does not bode well for entry into the crowded DPP-4 space.
Presenter at ADA meeting warns against "alarmist" reaction to imbalance in cancer rates for Bristol's SGLT-2 inhibitor dapagliflozin.
Part 2: High costs are built into the rare disease business model. Participants at a roundtable discussion led by Scrip at the J.P. Morgan Healthcare Conference talked about how much they are feeling the pressure on pricing.